ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Vincent K.H. Tam
Kirk R. Kanter
Jerrold H. Levy
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miller, B. E.
Right arrow Articles by Levy, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, B. E.
Right arrow Articles by Levy, J. H.

Ann Thorac Surg 1998;66:535-540
© 1998 The Society of Thoracic Surgeons

Original articles: cardiovascular

Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations

Bruce E. Miller, MDa, Steven R. Tosone, MDa, Vincent K.H. Tam, MDb, Kirk R. Kanter, MDb, Nina A. Guzzetta, MDa, James M. Bailey, MD, PhDa, Jerrold H. Levy, MDa

a Department of Anesthesiology, Emory University School of Medicine and Egleston Children’s Hospital at Emory University, Atlanta, Georgia, USA
b Division of Cardiothoracic Surgery, Department of Surgery, Emory University School of Medicine and Egleston Children’s Hospital at Emory University, Atlanta, Georgia, USA

Accepted for publication March 27, 1998.

Address reprint requests to Dr Miller, Department of Anesthesiology, Egleston Children’s Hospital at Emory University, 1405 Clifton Rd, NE, Atlanta, GA 30322

Background. Aprotinin consistently reduces blood loss and transfusion requirements in adults during and after cardiac surgical procedures, but its effectiveness in children is debated. We evaluated the hemostatic and economic effects of aprotinin in children undergoing reoperative cardiac procedures with cardiopulmonary bypass.

Methods. Control, low-dose aprotinin, and high-dose aprotinin groups were established with 15 children per group. Platelet counts, fibrinogen levels, and thromboelastographic values at baseline and after protamine sulfate administration, number of blood product transfusions, and 6-hour and 24-hour chest tube drainage were used to evaluate the effects of aprotinin on postbypass coagulopathies. Time needed for skin closure after protamine administration and lengths of stay in the intensive care unit and the hospital were recorded prospectively to determine the economic impact of aprotinin.

Results. Coagulation tests performed after protamine administration rarely demonstrated fibrinolysis but did show significant decreases in platelet and fibrinogen levels and function. The thromboelastographic variables indicated a preservation of platelet function by aprotinin. Decreased blood product transfusions, shortened skin closure times, and shortened durations of intensive care unit and hospital stays were found in the aprotinin groups, most significantly in the high-dose group with a subsequent average reduction of nearly $3,000 in patient charges.

Conclusions. In children undergoing reoperative cardiac surgical procedures, aprotinin is effective in attenuating postbypass coagulopathies, decreasing blood product exposure, improving clinical outcome, and reducing patient charges.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
N. S. Wilder, M. N. Kavarana, T. Voepel-Lewis, T. Paugh, T. Lee, and R. G. Ohye
Efficacy and Safety of Aprotinin in Neonatal Congenital Heart Operations
Ann. Thorac. Surg., September 1, 2011; 92(3): 958 - 963.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
Y.-M. Tae, J. G. Kwak, B.-H. Kim, I.-J. Jang, and W.-H. Kim
Population Pharmacokinetic Analysis and Dosing Regimen Optimization of Aprotinin in Neonates and Young Infants Undergoing Cardiopulmonary Bypass
J. Clin. Pharmacol., August 1, 2011; 51(8): 1163 - 1176.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
H. M. Homi, H. Sheng, G. M. Arepally, G. B. Mackensen, and H. P. Grocott
Aprotinin Improves Functional Outcome but Not Cerebral Infarct Size in an Experimental Model of Stroke During Cardiopulmonary Bypass
Anesth. Analg., July 1, 2010; 111(1): 38 - 45.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
N. A. Guzzetta, F. M. Evans, E. S. Rosenberg, T. M. Fazlollah, M. J. Baker, E. C. Wilson, A. M. Kaiser, S. R. Tosone, and B. E. Miller
The Impact of Aprotinin on Postoperative Renal Dysfunction in Neonates Undergoing Cardiopulmonary Bypass: A Retrospective Analysis
Anesth. Analg., February 1, 2009; 108(2): 448 - 455.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
C. L. Backer, A. M. Kelle, R. D. Stewart, S. C. Suresh, F. N. Ali, R. A. Cohn, R. Seshadri, and C. Mavroudis
Aprotinin is safe in pediatric patients undergoing cardiac surgery.
J. Thorac. Cardiovasc. Surg., December 1, 2007; 134(6): 1421 - 1428.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. Jaggers and J. H. Lawson
Coagulopathy and Inflammation in Neonatal Heart Surgery: Mechanisms and Strategies
Ann. Thorac. Surg., June 1, 2006; 81(6): S2360 - S2366.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
D. M. Arnold, D. A. Fergusson, A. K.C. Chan, R. J. Cook, G. A. Fraser, W. Lim, M. A. Blajchman, and D. J. Cook
Avoiding transfusions in children undergoing cardiac surgery: a meta-analysis of randomized trials of aprotinin.
Anesth. Analg., March 1, 2006; 102(3): 731 - 737.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
W. C. Oliver Jr, D. N. Fass, G. A. Nuttall, J. A. Dearani, L. M. Schrader, D. R. Schroeder, M. H. Ereth, and F. J. Puga
Variability of plasma aprotinin concentrations in pediatric patients undergoing cardiac surgery
J. Thorac. Cardiovasc. Surg., June 1, 2004; 127(6): 1670 - 1677.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. M. Costello, C. L. Backer, A. de Hoyos, H. J. Binns, and C. Mavroudis
Aprotinin reduces operative closure time and blood product use after pediatric bypass
Ann. Thorac. Surg., April 1, 2003; 75(4): 1261 - 1266.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
H. Mossinger, W. Dietrich, S. L. Braun, M. Jochum, H. Meisner, and J. A. Richter
High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery
Ann. Thorac. Surg., February 1, 2003; 75(2): 430 - 437.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. H. Levy and K. A. Tanaka
Inflammatory response to cardiopulmonary bypass
Ann. Thorac. Surg., February 1, 2003; 75(2): S715 - S720.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
E. R. Stephenson Jr and J. L. Myers
Pediatric cardiopulmonary bypass
Ann. Thorac. Surg., December 1, 2001; 72(6): 2176 - 2177.
[Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
L. A. Gramlich and S. D. Barnes
Aprotinin Use in Pediatric Cardiac Surgery
Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2001; 5(1): 117 - 121.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
L. H. Edmunds Jr
The quill passes
Ann. Thorac. Surg., July 1, 2000; 70(1): 1 - 2.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
A. M. Scheule, W. Beierlein, S. Arnold, F. S. Eckstein, J. M. Albes, and G. Ziemer
The Significance of Preformed Aprotinin-Specific Antibodies in Cardiosurgical Patients
Anesth. Analg., February 1, 2000; 90(2): 262 - 262.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1998 by The Society of Thoracic Surgeons.